TY - JOUR
T1 - Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine
AU - Ouyang, Huaqiang
AU - Wang, Peng
AU - Meng, Zhiqiang
AU - Chen, Zhen
AU - Yu, Er'Xin
AU - Jin, Huan
AU - Chang, David Z.
AU - Liao, Zhongxing
AU - Cohen, Lorenzo
AU - Liu, Luming
PY - 2011/1
Y1 - 2011/1
N2 - Objective: To explore the utility of multidisciplinary approaches in the treatment of patients with pancreatic cancer with liver metastases (PCLM). Methods: From 2002 to 2007, a total of 164 consecutive patients with PCLM treated with chemotherapy, radiation therapy, and/or Chinese herbal medicine were included in this study. Clinical parameters, treatments received, and survival time from initial diagnosis were analyzed. Results: Of the 164 patients, 113 (69%) were men and 51 (31%) were women, with median age of 58 years. One hundred thirty-two patients (80%) had synchronous liver metastases, and 57 patients (35%) had extrahepatic metastases. Overall median survival time of the 164 patients was 4.7 months; 23 (14%) were alive at least 12 months after initial diagnosis of liver metastases. Karnofsky performance status of less than 80, weight loss (>10% within 6 months), ascites, and carbohydrate antigen 19-9 of 1000 U/mL or greater were the most relevant predictors of poor survival. Multivariate analysis showed that chemotherapy and Chinese herbal medicine were protective factors. Conclusions: Multimodality treatment is well tolerated by patients with PCLM and may be effective in prolonging their survival. Awareness of the implications of these prognostic factors may assist in evaluating the survival potential of patients and selecting the most appropriate treatments.
AB - Objective: To explore the utility of multidisciplinary approaches in the treatment of patients with pancreatic cancer with liver metastases (PCLM). Methods: From 2002 to 2007, a total of 164 consecutive patients with PCLM treated with chemotherapy, radiation therapy, and/or Chinese herbal medicine were included in this study. Clinical parameters, treatments received, and survival time from initial diagnosis were analyzed. Results: Of the 164 patients, 113 (69%) were men and 51 (31%) were women, with median age of 58 years. One hundred thirty-two patients (80%) had synchronous liver metastases, and 57 patients (35%) had extrahepatic metastases. Overall median survival time of the 164 patients was 4.7 months; 23 (14%) were alive at least 12 months after initial diagnosis of liver metastases. Karnofsky performance status of less than 80, weight loss (>10% within 6 months), ascites, and carbohydrate antigen 19-9 of 1000 U/mL or greater were the most relevant predictors of poor survival. Multivariate analysis showed that chemotherapy and Chinese herbal medicine were protective factors. Conclusions: Multimodality treatment is well tolerated by patients with PCLM and may be effective in prolonging their survival. Awareness of the implications of these prognostic factors may assist in evaluating the survival potential of patients and selecting the most appropriate treatments.
KW - liver metastases
KW - multimodality treatment
KW - pancreatic cancer
KW - prognosis
UR - http://www.scopus.com/inward/record.url?scp=78650959439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650959439&partnerID=8YFLogxK
U2 - 10.1097/MPA.0b013e3181e6e398
DO - 10.1097/MPA.0b013e3181e6e398
M3 - Article
C2 - 20683216
AN - SCOPUS:78650959439
SN - 0885-3177
VL - 40
SP - 120
EP - 125
JO - Pancreas
JF - Pancreas
IS - 1
ER -